Moreover, FTO activated the FAK signaling pathway, and the pro-metastatic effects of FTO were suppressed by defactinib (VS6063), a selective FAK inhibitor [28], indicating a novel treatment strategy for NSCLC metastasis. This evidence concerns the gene FTO and non-small cell lung carcinoma.